LANDMARK DRUG CORP. v. OPTUM RX

CourtDistrict Court, D. New Jersey
DecidedFebruary 8, 2024
Docket3:24-cv-00024
StatusUnknown

This text of LANDMARK DRUG CORP. v. OPTUM RX (LANDMARK DRUG CORP. v. OPTUM RX) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
LANDMARK DRUG CORP. v. OPTUM RX, (D.N.J. 2024).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

LANDMARK DRUG CORP., Plaintiff, . Civil Action No. 24-24 (MAS) (DEA) “ MEMORANDUM ORDER OPTUM RX, Defendant.

SHIPP, District Judge This matter comes before the Court upon Defendant Optum Rx’s (“Optum”) Motion to Dismiss (ECF No. 5), or in the alternative, to stay proceedings pending arbitration pursuant to Federal Rule of Civil Procedure’ 12(b)(6) and 9 U.S.C. § 3.7 Plaintiff Landmark Drug Corp. (“Plaintiff” or “Landmark”) opposed the Motion.’ (ECF No. 9.) The Court has carefully considered the parties’ submissions and decides the motion without oral argument pursuant to Local Civil

' Unless otherwise noted, all references to “Rule” or “Rules” hereinafter refer to the Federal Rules of Civil Procedure. * Optum also filed an opposition to Plaintiff's Motion for Injunctive Relief (see ECF No. 6) and Plaintiff replied (ECF No. 9). Plaintiff did not file a Motion for Injunctive Relief on this Court’s docket. Rather, Plaintiff filed a Motion in Support of an Order to Show Cause Seeking Temporary Restraints and Injunctive Relief in the Superior Court of New Jersey, Chancery Division (“State Court”), prior to removal. (See State Docket No. SOM-12071-23; see also Pl.’s Moving Br. 10- 28, ECF No. 1-3.) The findings set forth herein shall effectively resolve the issues presented in Plaintiff's State Court motion. 3 Optum has yet to file a reply brief. Having fully reviewed the substance of the parties’ submissions, the Court need not have this matter fully briefed before ruling on the merits of the pending motion.

Rule 78.1. For the reasons stated herein, the Court denies Optum’s Motion to Dismiss. The Court will, however, grant Optum’s alternative request to stay this matter pending further clarification from the arbitrator on the arbitrability of Plaintiff?s request for a preliminary injunction. I. BACKGROUND A. Factual Background Landmark is a retail pharmacy located in North Plainfield, New Jersey. (Compl. 3, ECF No. 1-1.) Optum is a pharmacy benefit manager (“PBM”) and provides pharmacy benefit services to in-network pharmacies such as Landmark, which includes handling network pharmacy claims, mail order pharmacy services, drug utilization review, and formulary management. (/d. { 4.) Since 2009, Landmark has participated in Optum’s network through a contract with Pharmacy First, a Pharmacy Service Administrative Organization (“PSAO”) that contracts directly with Optum. (/d. { 6.) As all sides agree, pharmacies participating in Optum’s network are governed and bound by the terms of Optum’s Pharmacy Provider Manual (“PPM”). Ud. § 5.) Plaintiff does not dispute that, as a network pharmacy, it is subject to the terms of the PPM, including the dispute resolution procedures contained in Section L, titled “Alternative Dispute Resolution and Arbitration.” (/d., Ex. A.) Section L details dispute resolution procedures and requirements. (/d.) Specifically, a “dispute” is defined as: any and all issues, disputes, and/or controversies between the parties, including, but not limited to all disputes relating in any way to the parties’ relationship, the terms of the Provider Network Agreement . . . and the Pharmacy Provider’s status in the Administrator’s network, ... For avoidance of doubt, all termination disputes are still subject to arbitration.

Section L also outlines a set of procedures to be followed where Optum and a contracting party are involved in a “dispute.” (/d.) In relevant part, the parties agree to “engage in good faith discussions to try to resolve” any disputes, and if they are unable to resolve the dispute within thirty days, “either party may request in writing a meeting or telephone conference to resolve the dispute.” (/d.) Where the parties are still unable to resolve the dispute, either party may commence arbitration. Ud.) The PPM contains broad language in favor of arbitration, providing that arbitrators appointed by the American Arbitration Association (“AAA”): shall decide any and all questions regarding arbitrability or the formation, scope, validity, and/or interpretation of the parties’ agreement to arbitrate. For further avoidance of doubt, all [d]isputes including [d]isputes regarding termination hereof or nonrenewal hereof... are subject to the arbitration process described herein. (/d.) Parties subject to the PPM further acknowledge that neither party has “the right to litigate a [d]ispute in court, and that neither will have a right to a trial by a judge or jury, and the right to discovery is limited. The parties each waive all such rights by agreeing that all disputes must be resolved exclusively in arbitration.” Id. (emphasis in original).) The dispute at issue arose between Plaintiff and Optum in February 2023. Ud, Ex. B.) On February 10, 2023, Optum sent correspondence to Plaintiff stating that Plaintiff was subject to a routine audit under the terms of the PPM. Ud.) That audit revealed: (1) one instance where Landmark “submitted claims for a different strength than what is indicated on the corresponding prescription records”; (2) an inventory shortage; and (3) three instances of an “incorrect DAW code” submission. (/d.) Optum provided its own evidence that Landmark made overpayments in the amount of $47,178.04. (/d.) In subsequent correspondence on March 11, 2023, Plaintiff contested Optum’s findings and asserted that the evidence “did not support [Optum’s] findings” as to the claims submitted by

Landmark. (/d., Ex. C.) Optum rejected Plaintiff's opposition and notified Plaintiff that it would be terminated from its network as of October 6, 2023. Ud. J§ 15, 16.) Plaintiff appealed Optum’s determinations and internal hearings were held on October 4 and November 29, 2023, respectively. Ud. {| 17, 28, 31.) Optum upheld its decision and issued a final determination that Landmark would be removed from its pharmacy network as of December 7, 2023. Ud. J§ 32-34.) Notably, and despite these findings, it appears that Optum has allowed Landmark to continue servicing its customers by providing prescription medications through Optum. (ECF No. 1-3, at *43*.) B. Procedural History Based on the terms of the PPM, Plaintiff filed a demand for arbitration® with the AAA on December 4, 2023. (Compl. { 36.) The same day, Plaintiff filed the instant Complaint and order to show cause in the Superior Court of New Jersey, Chancery Division (“State Court”) to enjoin Optum from terminating Landmark from its network until the completion of the arbitration proceedings. (See id.) The Complaint outlines: (1) a request for temporary restraints to maintain the status quo and allowing Landmark’s patients to obtain their prescriptions during the pendency of the arbitration process; (2) a request for permanent injunctive relief “compelling Optum to proceed with . . . arbitration consistent with the procedures” prescribed in the PPM; and (3) a request to enjoin Optum from terminating Landmark as a participating pharmacy until a determination is rendered in the arbitration proceeding. (/d.)

* Page numbers preceded by an asterisk refer to the page numbers atop the ECF header. > Plaintiff indicates that the arbitration proceeding for this matter is ongoing and in its “early stages.” (Pl.’s Reply Br. in Supp. of Preliminary Injunction, ECF No. 9.)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Prima Paint Corp. v. Flood & Conklin Mfg. Co.
388 U.S. 395 (Supreme Court, 1967)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Karen Malleus v. John George
641 F.3d 560 (Third Circuit, 2011)
Teradyne, Inc. v. Mostek Corp.
797 F.2d 43 (First Circuit, 1986)
Ortho Pharmaceutical Corporation v. Amgen, Inc.
882 F.2d 806 (Third Circuit, 1989)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
Thompson v. Nienaber
239 F. Supp. 2d 478 (D. New Jersey, 2002)
Kehr Packages, Inc. v. Fidelcor, Inc.
926 F.2d 1406 (Third Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
LANDMARK DRUG CORP. v. OPTUM RX, Counsel Stack Legal Research, https://law.counselstack.com/opinion/landmark-drug-corp-v-optum-rx-njd-2024.